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ABSTRACT  
 
5-Fluorouracil (5-FU) is chemotherapeutic agents used in breast cancer treatment. However 5-
FU has low effectiveness as chemotherapeutic agent after longterm used. 5-FU usually combined with 
other compounds to increase its effectivity. Bawang Dayak has been widely used empirically as a 
cancer treatment, especially breast cancer. The aim of this study was to determine the sensitivity of 5-
FU as cytotoxic agent against T47D breast cancer cells and their combination with extract of Bawang 
Dayak (EBD), to determine apoptotic induction mechanism, and the inhibitory effect of T47D breast 
cancer cell cycle. The cytotoxicity properties were determined using the MTT method with the 
concetration series of 5-FU (0-600 μg/mL) and EBD (0-250 μg/mL). The combination between 5-FU 
(2-250 μg/mL and EBD (5-50 μg/mL) was used for combination treatment on T47D cells. The 
apoptotic cells after treatment were determined by propidium iodide/annexin V reagent using 
flowcytometry. The modulation effect of combination treatment between 5-FU and EBD was 
performed by determination of  DNA content using flowcytometry. The treatment of 5-FU and EBD 
inhibited T47D cell growth with IC50 value 274 μg/mL and 75 μg/mL, respectively. The combination 
therapy of 5-FU and EBD resulted a mild to strong synergistic effect, with combination index (CI) 
0.829 and 0.779. The combined treatment (125μg/mL 5-FU and 25μg/mL EBD) induced apoptosis in 
T47D cells by 21.33%. This combination caused 57.11% cell accumulation in G0-G1 phase, that  
greater than control grup (41.20%). The combination treatment (5-FU and EBD) cause cell distubance 
and damage that lead to G0-G1 phase cell cycle arrest. The cell cycle can not proceed to the next phase. 
EBD produce synergistic effect when used as breast cancer co-chemotherapy with 5-FU. It was 
particularly able to induce apoptosis against T47D cells followed by G0-G1 phase accumulation. The 
extract of Bawang Dayak has a high potential to be developed as co-chemotherapy in breast cancer. 
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INTRODUCTION 
Cancer is the second most prevalent disease in the world after heart and blood vessel diseases. 
International Agency for Research on Cancer (IARC) in 2012 reports the breast cancer in the world 
reaches second ranked after lung cancer on incidency and mortality, which is 43.1% and 17.9%, 
respectively. The incidence and death rates from breast cancer in Indonesia were 48,998 and 19,750 
(Ministry of Health Republic of Indonesia, 2014). The high prevalence of cancer in Indonesia requires 
greater attention to find out the solution of the obstacle of breast cancer therapy. 
One of the breast cancer chemotherapy is 5-fluorouracil (5-FU). 5-FU has adverse and toxic 
effects such as diarrhea and myelotoxicity (National Comprehensive Cancer Network, 2014). The 
effectiveness of 5-FU as a chemotherapeutic agent is only 15%, so it need to combined with other 
compounds to improve its effectiveness of therapy (Meyerhardt and Mayer, 2005). The combination is 
expected produced a additive to synergistic effect. The compounds that extracted and isolated from 
medicinal plants that have been empirically used as cancer chemoprevention and co-chemotherapy for 
increasing the potency of chemotherapy agents that already establish as cancer chemotherapeutic 
agent.  
Bawang Dayak (Sisyrinchium palmifolium L.) is a typical plant of Central Kalimantan that has 
been empirically used for the treatment of hypertension, diabetes, hyperlipidemia, stroke, and cancer, 
and particularly breast cancer (Galingging, 2009). Bawang Dayak bulbs contain flavonoid compounds, 
polyphenols, monoterpenes, sesquiterpenes, and steroids. Bawang Dayak ethanolic extract has strong 
antioxidant activity with IC50 value of 46.14 ppm (Hidayah et al., 2015). The ethanolic extract of 
Bawang Dayak has cytotoxic effect on HT29 colon cell carcinoma with IC50 of 3.125 ppm, while IC50 
of 5-FU was 150 ppm (Yusni, 2008). Sudarmawan (2009) reported Bawang Dayak ethanolic extract 
has activity against breast cancer cell T47D with IC50 value of 125 ppm. Thus Bawang Dayak 
ethanolic extract may contain potent active compounds to be developed as anti-cancer. 
In this research, ethanolic extract of Bawang Dayak is combined with 5-FU used to treat T47D 
breast cancer cell. The study was conducted by comparing the cytotoxicity effects of 5-FU and 
Bawang Dayak ethanolic extract as a single treatment as well as a combination of both, observing 
proliferative inhibition, and T47D breast cancer cell apoptosis. The combination of 5-FU and Bawang 
Dayak ethanolic extract has been shown to increase the effectiveness of 5-FU therapy in T47D breast 
cancer. 
 
MATERIALS AND METHODS    
Materials 
Bawang Dayak bulbs are obtained from Samarinda, East Kalimantan. Plant identification was 
done at the Laboratory of Plant Taxonomy, Faculty of Biology, University of Jenderal Soedirman, 
70% ethanol, 5-FU, T47D cells (Parasitology Laboratory, Faculty of Medicine, Gadjah Mada 
University). DMEM (Sigma Aldrich)-containing media Fetal Bovine Serum (FBS) (Gibco) 10% (v / v) 
and 2% (v / v) penicillin-streptomycin antibiotics (Sigma Aldrich), dimethyl sulfoxide (DMSO) 
(Sigma Aldrich), 3-(4,5 dimethyltoyo-2-yl) 2,5-diphenyltetrazolium bromide (MTT) (Sigma Aldrich) 
5 mg/ml, Annexin V (Merck), and propidium iodide (Merck). 
 
Methods 
Extract Preparation 
Bawang Dayak bulbs were washed with clean water, then dried and grounded with a grinder and 
then put into a sealed plastic bag (MOH, 2000 ). A total of 100 grams of Bawang Dayak bulb powders 
were macerated with 1 liter of ethanol 70% for 3 days, the comparison between simplicia and solvent 
was 1:10. After 3 days, then filtered the filtrate and thickened using a rotary vaccum evaporator until 
the viscosity was slightly viscous. This process was continued by evaporated on a waterbath with a 
temperature of 60
o
C to obtain ethanol condensed extract. The extract is placed at 4
o
C prior to used. 
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The cytotoxicity assay of single and combination using MTT  
The T47D cells with a density of 10
4
 cells/well were distributed into 96 well plates and 
incubated for 24 hours. Cells were treated with ethanolic extract of Bawang Dayak (EBD) (25, 50, 
100, 175, 250, 500, and 1000 μg/mL) or 5-FU (200, 300, 400, 500, and 600, 700, 800 μg/mL) for a 
single test. While for the combination test used EBD (5, 10, 25, and 50 μg/mL) and 5-FU (25, 50, 125, 
and 250 μg/mL), then incubated for 24 hours. At the end of the incubation, the culture medium was 
removed, and washed with FBS. Then we added 100 μl MTT 0.5 mg/mL into each well and incubated 
again for 4 hours at 37
0
C. After  incubation we added 100 μl SDS 10% in 0.1 N HCl solution. Cells 
were incubated overnight at room temperature and shielded from light, then read with ELISA reader at 
λ 595 nm (CCRC, 2013). 
 
Apoptotic assay using PI/Annexin V 
The T47D Cells with a density of 4x10
5
 cells/well were distributed into 6 well plate and 
incubated for 24 hours. At the end of the cell incubation was washed with FBS 500 μL. Cells were 
given single treatment of EBD (25 μg / mL), single 5-FU (50 and 125 μg / mL), and a combination of 
both agents. The combination treatment used at this study are EBD 25 μg / mL – 5-FU 50 μg / mL and 
EBD 25 μg / mL – 5-FU 125 μg / mL. Then reincubated in CO2 incubator for 24 hours. At the end of 
the incubation time, the cell condition is documented. Cells were harvested using 0.25% trypsin-
EDTA and added subsequently added 400 μL PI/Annexin-V-Fluos-labeling solution in each microtube 
then homogenized carefully using vortex. Each microtube is wrapped with aluminum foil and marked 
on the top of microtube. All was incubated in waterbath 37
0
C for 10 minutes to activate RNAse. Cell 
suspension is transferred into flowcyto-tube through filter (nylon fabric or glass cloth) then analysed 
using flowcytometer (CCRC, 2013a). 
 
Cell cycle assay using Flowcytometry 
Cells with a density of 4x10
5
 cells/well (4x10
5
 cells/1000 μL culture medium) were distributed 
into 6 wells plate and then incubated for 24 hours. Cells were treated with EBD (25 μg/ mL) and 5-FU 
(125 μg mL) and as control cells were given 1000 μL culture medium. Then reincubated in CO2 
incubator for 24 hours. At the end of the incubation time, the cell morphological condition was 
documented. The harvested cells were then fixed with ethanol 70%, -20
0
C and washed with PBS. Cells 
were added with 400 μL flowcytometry reagents in each microtube, resuspended until homogen. Each 
microtube is wrapped with aluminum foil and marked on the top of eppendorf. All microtube was 
incubated in waterbath 37
0
C for 10 minutes to activate RNAse. The cell suspension is transferred into 
flowcyto-tube through filter (nylon fabric or glass cloth) the analysed using flowcytometer to 
determine cell cycle profile. The data was analyzed by a cell quest program to observe the distribution 
of cells in each phase of cell cycle. Flowcytometry is performed with a light emission of 488 nm and 
with a medium speed of 500 cells/second (CCRC, 2013 b). 
 
Data Analysis 
The cytotoxicity assay for single compound 
The data obtained as absorbance of each well used to calculate cell viability (live cell 
percentage). The formula is:  
 
% viable =                                                                                         x100% 
 
IC50 (Inhibitory Concentration 50%) is determined by the logarithmic equation between the 
absorbance value and the concentration of the extract. 
 
The cytotoxicity assay for combination treatment 
The effect of  the combination between EBD and 5-FU were analysed using the combination 
Index (CI) value with the equation (Reynold and Maurer, 2005):  
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CI = (D)1/(DX)1+ (D)2/(DX)2 
 
Description:  
DX, the concentration of a single compound is required to give effect as much as the combined one, D1 
and D2, the concentration of the two compounds (1 and 2) is used as combination treatment.  
 
Table I . Interpretation of CI value  (Reynold and Maurer, 2005) 
 
CI Values Interpretation 
<0.1 Very strong synergism  
0.1 – 0.3 Strong sinergism 
0.3 – 0.7 Synergism  
0.7 – 0.9 Mild to moderate synergism  
0.9 – 1.1 Additive 
1.1 – 1.45 Mild to moderate antagonism  
1.45 – 3.3 Antagonism 
>3.3 Strong to very strong 
antagonism  
 
Result and Dicussions 
The EBD and 5-FU treatment resulted morphologically changing on T47D cells. Most of cell 
population was detached from tissue culture dish than become floating in culture medium. Most of 
detached cells became spherical shape and generated apoptotic bodies (Figure 1). 
 
 
 
 
 
 
 
 
 
Figure 1. The effect of 5-FU (600 μg/mL) and EBD (250 μg/mL) treatment against T47D cancer 
cells with a density of 10
4
 cells distributed on 96 wells, 24-hour incubation. 
Observations under an inverted microscope showed that there was a difference in cell 
morphology after treatment 
 
The effect of EBD on T47D cells viability are shown by a sigmoid curve as relation between 
EBD concentration versus viable cell (%). The treatment of EBD resulted inhibition of T47D cell 
viability with dose dependent manner while 5-FU resulted similar effect after various concentration 
treatment (Figure 2).  
 
 
 
 
 
 
 
 
 
 
EBD 250 µg/mL Untreated 5-FU 600 µg/mL 
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Figure 2. The effect of combination of EBD and 5-FU treatment on cell viability 
The sensitivity of T47D cells against EBD was determined by the IC50 value. EBD inhibited 
T47D cells growth after 24 hours incubation, with IC50 value 76 μg/mL. Bawang Dayak consisted 
several compounds affected the inhibition of T47D breast cancer cells viability. Bawang Dayak 
contain anthraquinone compound and one was determined as naphthoquinone. This active compound 
was suspected to be naphthoquinone that already known as an anticancer and antioxidant. This 
compound was usually present in vacuoles in the form of glycosides (Babula et al., 2009; Babula et 
al., 2005). 
5-FU resulted on T47D cell growth inhibition with The IC50 value 274 μg/mL that higher if 
compared with the previous research (2.97 μg/mL) (Sukardiman et al., 2014). The presence of 
hydroxyl and fluoro groups in 5-FU thought to contribute to its toxicity properties (Folmer et al., 2006 
and Kim, 2006). 5-FU is an antimetabolite that acts antagonistically with thymine against 
thimidylatesintase (TS) enzyme activity. 5-FU produces fluoridin-5`-triphosphate (FUTP) that 
combines into RNA and affects its function and fluorodeoxyuridate (FdUMP) that inhibits DNA 
replication (Longley and Johnston, 2007).  
The EBD and 5-FU treatments showed morphologicaly changes in T47D cells compared with 
controls (Figure 1). The EBD (250 μg/mL) treatment resulted more severe of T47D cell dead. The 
treatment of 5-FU (600 μg/mL) caused decreasing of T47D cell size. The changing of cell morphology 
may lead the decreasing of viability of T47D cells. 
The combination treatment of EBD and 5-FU might be increased the sensitivity of 5-FU 
chemotherapy agents against T47D breast cancer cells. It needs further determination of the 
combination treatment on combination cytotoxicity, apoptosis induction, and cell cycle inhibition 
assay. 
 
The potency of cytotoxicity effect of 5-FU dan EBD combination 
The cytotoxicity assays of 5-FU and EBD combination were performed using several 
concentrations below IC50 of EBD (5, 10, 25, and 50 μg/mL) and 5-FU (25, 50, 125, and 250 μg/mL). 
The combinations treatment decreased T47D cell viability, higher than the treatment of single one. The 
lowest of T47D cell viability was obtained after treated by combination of 5-FU-EBD (125 μg/mL - 50 
μg/mL (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The CI values of EBD and 5-FU on various concentration variations in T47D cells 
 
 
 The combination treatment resulted mild-moderate antagonists to strong synergis effect. The 
combination of 5-FU and EBD (125-5; 50-10;  125-10; 250-10; 25-25 μg/mL) resulted synergistic 
effect with the CI values above 0.3. From these results proved that EBD has the potential to be used as 
a 5-FU co-chemotherapy agent. Giving a combination of 5-FU and EBD at that concentrations 
provides a synergistic effect until very strong synergist against T47D breast cancer cells. 
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The cell death induction of T47D cell after 5-FU and EBD treatment 
The apoptotic induction result various changes in the plasma membrane including changes in 
permeability and lipid membrane. During apoptosis major changes occur in lipid membranes where 
phosphatidilserin (PS) is translocated from the inner to outer membrane. Phosphatidilserine (PS) binds 
to Annexin V and this change can be observed by cell incubation with Annexin V. In normal living 
cells, phosphatidylserine (PS) lies on the cytoplasmic surface of the membrane cell. During apoptotic 
induction, rapid changes occur in phospholipids in cells that cause changes in PS positions on the cell 
surface. The bonding ability between Annexin V and PS occurs very quickly with the presence of Ca
2+
 
ions. PS translocation on the cell surface precedes nuclear changes and DNA fragmentation. These 
changing will lead to apoptotic cell death. The appearance of  Annexin V and PS bonding could be 
used as a marker of early apoptosis (Ormerod, 2000). 
The apoptosis assay by flowcytometry measures the percentage of cell death by apoptosis and 
necrosis, as well as the number of cells that remain normally alive. The single treatment both of 5-FU 
and EBD induced the increasing of of cell death on T47D cells. The cell death mechanism suspected 
trough apoptosis mechanism. The combinations treatment of 5-FU and EBD that used at this 
experiment are 50-25 and 125-25 μg/mL as the best combination that provide mild to moderate 
synergistic effect on T47D cells growth inhibition (Figure 4).  
 
 
 
Figure 4. The apoptosis induction effect after treated by 5-FU, EBD as single and combination 
treatment. The lower right (LR) quandrane indicates a living cell, lower left (LL) 
showing cells undergoing early apoptosis, upper left (UL) is showing a late apoptotic 
cell, and upper right (UR) is showing necrotizing cells 
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Table II. The effect of 5-FU and EBD as single and combination treatment on percentage of 
apoptotic and necrotic cells 
 
Treatment 
Concentration 
(μg/mL) 
Viable cells 
(LR)  
(%) 
Early 
apoptotic 
cells (LL)  
(%) 
Late 
apoptotic cells 
(UL)  
(%) 
Necrotic cells  
(UR)  
(%) 
Untreated 
cell 
- 91.28 ± 0.08 4.35 ± 0.01 3.64 ± 0.21 0.65 ± 0.01 
EBD 25 93.27 ± 0.68 1.52 ± 0.00 1.36 ± 0.01 4.39 ± 0.62 
5-FU 50 79.73 ± 0.12 10.10 ± 0.02 8.48 ± 0.05 1.72 ± 0.07 
5-FU 125 78.97 ± 0.14 10.37 ± 0.00 9.38 ± 0.09 1.31 ± 0.03 
5-FU-EBD 50-25 80.40 ± 0.23 14.61 ± 0.10 4.30 ± 0.06 0.73 ± 0.04 
5-FU-EBD 125-25 77.74 ± 0.35 16.05 ± 0.17  5.45 ± 0.06    0.85 ± 0.02 
 
The results of apoptotic observation using flowcytometer showed that EBD treatment at 25 
μg/mL concentration with 24 hours incubation time caused 2.88% of cells undergo apoptosis (an 
accumulation of 1.52% early apoptosis and 1.36% late apotosis), lower than untreated cells (7.99%, as 
an accumulation 4.35% early apoptosis and 3.64% late apoptosis). 5-FU treatment (50 μg/mL and 125 
μg/mL) after 24-hour incubation period resulted in 18.58% and 19.75% of cells apoptosis (as an 
accumulation of early and late apoptosis cells), respectively (Table III). The combination treatment 
elevated the persentage of apoptotic cells and particularly decreased the persentage of necrotic cells 
compared with single treatment either of 5-FU or EBD. These data suggest that EBD treatment can 
improve the ability of 5-FU in spurring the occurrence of apoptosis in T47D cells. The incresing 
number of apoptotic cell causes the decreasing of T47D cell viability. The cytotoxic effects also causes 
the cell cycle arrest. 
 
T47D cell cycle inhibition due to single and combinations treatment of 5-FU and EBD  
The accumulation of cells in the cell cycle is one of the main targets of anticancer agents. The 
largest cell accumulation in the 5-FU-EBD combination treatment at 125 μg/mL-25 μg/mL 
concentration was in the G0-G1 phase of 57.11%. The combination of 5-FU125 μg/mL - EBD 25 
μg/mL resulted G0-G1 phase arrest higher than untreated cells (Figure 5 and Table III).  
 
 
 
 
 
 
 
 
Figure 5. The T47D cell cycle profile without treatment (A) and after combination treatment 
(125 -25 μg/mL) (B) 
 
 
 
 
 
 
 
 
Marker Ev ents % Gated % Total Mean CV Median
All 20000 100.00 100.00 383.53 74.75 341.00
M1 2932 14.66 14.66 8.52 283.60 0.00
M5 4932 24.66 24.66 805.18 24.43 805.00
GO-G1 4639 23.20 23.20 211.64 7.82 209.00
S-phase 2573 12.86 12.86 296.54 9.50 296.00
G2-M 4973 24.87 24.87 390.92 5.80 391.00
Sample ID: A Total Ev ents: 20000
X Parameter: FL2-A FL2-Area (Linear)
Marker Ev ents % Gated % Total Mean CV Median
All 11237 100.00 56.18 295.20 27.52 285.00
GO-G1 4630 41.20 23.15 211.64 7.81 209.00
S-phase 2540 22.60 12.70 296.18 9.46 295.00
G2-M 4077 36.28 20.39 388.92 5.61 389.00
Sample ID: A Total Ev ents: 20000
X Parameter: FL2-A FL2-Area (Linear)
R1
M1
M5
GO-G1
S-phase
G2-M
GO-G1
S-phase
G2-M
Marker Ev ents % Gated % Total Mean CV Median
All 20000 100.00 100.00 260.14 87.51 215.00
M1 5727 28.63 28.63 22.48 199.07 0.00
M5 2657 13.29 13.29 699.50 27.47 652.00
GO-G1 6437 32.19 32.19 206.79 9.51 206.00
S-phase 1898 9.49 9.49 297.10 9.71 298.50
G2-M 3392 16.96 16.96 397.13 6.87 398.00
Sample ID: B Total Ev ents: 20000
X Parameter: FL2-A FL2-Area (Li ear)
Marker Ev ents % Gated % Total Mean CV Median
All 11174 100.00 55.87 273.21 32.13 231.00
GO-G1 6381 57.11 31.91 206.78 9.48 206.00
S-phase 1764 15.79 8.82 296.59 9.68 298.00
G2-M 2837 25.39 14.19 395.96 6.78 397.00
Sample ID: B Total Ev ents: 20000
X Parameter: FL2-A FL2-Area (Linear)
M1
M5
GO-G1
S-phase
G2-M
GO-G1
S-phase
G2-M
R1
B 
A 
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Table III. The distribution of T47D cells after treatment with a combination of 5-
FU and EBD 
 
Treatment  Concentration  
Phase (%) 
G0-G1 S-Phase G2-M 
Untreated cell - 41.20 22.60 36.28 
5-FU-EBD 125 μg/mL – 25 
μg/mL 
57.11 15.79 25.39 
 
At the previous experiment, Hidayah, et al., (2015) reported Bawang Dayak bulbs contain 
terpenoid group compounds. Ircinin is one of the terpenoid compounds reported to cause G1 arrest in 
skin cancer cells (Mayer and Gustafson, 2003). The natural sequiterpenoids particularly induce G1 
arrest on cell cycle progression through p21 and p27 induction. These proteins included in Cyclin 
Dependent Kinase inhibitors (CDKIs). Expression of p21 and p27 leads to a decrease in cyclin D 
levels so that no CDK4 and CDK6 activation occurs. Activation of CDK4 and CDK6 serves for the 
phosphorylation of Rb protein (retinoblastoma), so if there is blocking of CDK4 and CDK6 activation 
there is no phosphorylation of Rb protein. Unphosphorylated Rb will bind to the transcription factor 
E2F binding to DNA and inhibit the transcription of genes whose products are required for phase S 
cell cycle so that cells are retained in phase G0-G1 or G1 arrest (Kundu,  2012). The previous research 
by Guo et al. (2008) showed the largest cell accumulation in the 5-FU treatment of T47D cells 
occurred in G1 phase. 5-FU is an antimetabolite that acts antagonistically with thymine against the 
activity of thimidylate synthase (TS) enzyme. 5-Fluorouracil can not work on cells outside the cell 
(G0). 5-Fluorouracil only acts on cells that are active in the cell cycle where TS activity is required for 
the synthesis of the basic constituents of DNA. TS is expressed high in phase G1 via an intermediate 
transcriptional activity of E2F. The TS itself directly synthesizes the necessary dUMP precursors in 
the synthesis phase. Treatment with 5-FU in cancer cells can cause cell accumulation in G1 phase and 
early synthesis phase (G1 arrest). 
The combination treatment of EBD and 5-FU was conducted to find out how the combination 
effect on T47D cell cycle. In combination treatment, the largest accumulation was in the G0-G1 phase 
of 57.11%, in which phase G0-G1 protein synthesis spurred cell division which will form spindle 
cleavage. Provision of 5-FU and EBD combination treatments causes disturbance and damage to cells 
that cause cell breaks in G0-G1 phase and can not proceed to S phase. 
 
CONCLUSSION 
The combination treatment of 5-fluorouracil and Bawang Dayak ethanolic extract has a strong 
synergistic effect as breast cancer co-chemotherapy through apoptotic induction and cell accumulation 
in G0-G1 phase on breast cancer, T47D cells. 
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